Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives Average Rating of “Moderate Buy” from Analysts

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) has been assigned an average recommendation of “Moderate Buy” from the six ratings firms that are currently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $5.92.

XERS has been the subject of several research reports. Piper Sandler reiterated a “neutral” rating and issued a $4.00 target price (up from $3.00) on shares of Xeris Biopharma in a report on Friday, March 7th. Leerink Partners boosted their price target on Xeris Biopharma from $5.00 to $6.00 and gave the stock an “outperform” rating in a research report on Friday, March 7th. Craig Hallum boosted their price target on Xeris Biopharma from $5.00 to $6.50 and gave the stock a “buy” rating in a research report on Friday, March 7th. Jefferies Financial Group reissued a “buy” rating and issued a $6.00 price target (up from $4.00) on shares of Xeris Biopharma in a research report on Wednesday, January 29th. Finally, HC Wainwright reissued a “buy” rating and issued a $8.00 price target (up from $6.60) on shares of Xeris Biopharma in a research report on Friday, March 7th.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. NewEdge Advisors LLC acquired a new position in Xeris Biopharma during the 4th quarter valued at about $34,000. R Squared Ltd acquired a new position in Xeris Biopharma during the 4th quarter valued at about $42,000. Wealth Enhancement Advisory Services LLC acquired a new position in Xeris Biopharma during the 3rd quarter valued at about $35,000. Cibc World Markets Corp acquired a new position in Xeris Biopharma during the 4th quarter valued at about $44,000. Finally, Raymond James Financial Inc. acquired a new position in Xeris Biopharma during the 4th quarter valued at about $45,000. 42.75% of the stock is owned by institutional investors and hedge funds.

Xeris Biopharma Trading Up 5.7 %

Shares of XERS stock opened at $4.82 on Monday. Xeris Biopharma has a twelve month low of $1.69 and a twelve month high of $4.90. The stock has a market capitalization of $741.99 million, a price-to-earnings ratio of -10.71 and a beta of 2.32. The stock has a fifty day simple moving average of $3.68 and a two-hundred day simple moving average of $3.32.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.